BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

7:10 PM
 | 
Jul 01, 2009
 |  BC Extra  |  Top Story

Biogen Idec, Acorda in Fampridine-SR deal

Acorda Therapeutics Inc. (NASDAQ:ACOR) granted Biogen Idec Inc. (NASDAQ:BIIB) exclusive, worldwide rights outside the U.S. to develop and commercialize Fampridine-SR. Acorda will receive $110 million up front and is eligible for $400 million in milestones. Acorda will...

Read the full 179 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >